Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsConnectiCare Viltepso Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentConnectiCarePolicy C20585-A

    Viltepso (viltolarsen) Coverage Criteria

    Customize your policy alerts

    Sign up for ConnectiCare Policy C20585-A alerts

    Get alerted when Policy C20585-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage determinations for Viltepso (viltolarsen), including use for Duchenne muscular dystrophy and other indications; the policy considers Viltepso not medically necessary because clinical benefit has not been established, subject to benefit eligibility and plan terms.

    Policy Summary
    PayerConnectiCare
    PolicyViltepso (viltolarsen) Coverage Criteria
    Policy CodePolicy C20585-A
    Change TypeNo material clinical or coverage changes
    Effective DateJun 6, 2026
    Next Review DateApr 1, 2027
    Key ActionSubmit patient records, test results, and provider credentials when requested for coverage determination.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Not medically necessaryCoverage stance
    DMDDiagnosis
    IVAdministration
    Accelerated approvalFDA approval basis

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    J1427
    HCPCS code
    No changesReview outcome

    Coverage Determination

    Not medically necessary

    Viltepso is considered not medically necessary for all indications.

    Not medically necessary: Viltepso (viltolarsen) is not medically necessary because there is insufficient evidence of therapeutic value and clinical benefit has not been established.

    This applies to all indications, including but not limited to Duchenne muscular dystrophy (DMD).

    Use of Viltepso (viltolarsen) for the applicable labeled use is distinguished from all other uses. Uses outside the applicable labeled indication are considered experimental or investigational.

    All other uses of Viltepso (viltolarsen) are considered experimental or investigational and are reviewed under the Molina Off-Label policy.

    Viltepso is considered not medically necessary for all indications, including Duchenne muscular dystrophy, because there is insufficient evidence of therapeutic value and confirmed clinical benefit has not been established.

    Coding Information

    HCPCS CodeHCPCS
    J1427Injection, viltolarsen, 10 mg

    Provider and Billing Guidance

    Documentation Required

    Submit clinical and provider documentation

    Make additional documentation available when requested for coverage determination, quality improvement, and fraud, waste, and abuse prevention. Required materials may include patient records, test results, and the credentials of the provider ordering or performing the drug or service.

    • Documentation must support medical necessity, non-investigational or non-experimental status, and that the service is within the member’s benefits.
    • Insufficient or inappropriate documentation may result in denied reimbursement or other action.
    Billing Rule

    Use industry-standard coding

    Providers and facilities must use industry-standard coding practices for all claim submissions. For viltolarsen, the listed HCPCS code is J1427 (injection, viltolarsen, 10 mg).

    Drug and Disease Background

    Viltepso (viltolarsen) is indicated for patients with Duchenne muscular dystrophy who have a confirmed DMD gene mutation amenable to exon 53 skipping. The FDA granted accelerated approval based on increased dystrophin production, which was considered reasonably likely to predict clinical benefit; however, confirmed clinical benefit has not been established and is being evaluated in an ongoing confirmatory trial.

    Key Definitions

    Accelerated approval
    DefinitionAn FDA approval pathway that permits availability based on an effect reasonably likely to predict clinical benefit while a confirmatory clinical trial is conducted to verify and describe that benefit.
    Mutation amenable to exon 53 skipping
    DefinitionA DMD gene mutation that can be targeted by skipping exon 53 during dystrophin production.
    Duchenne muscular dystrophy (DMD)
    DefinitionA rare, progressive, X-linked recessive genetic disorder caused by mutations in the dystrophin gene that lead to absent or defective dystrophin protein and progressive muscle weakness.
    Policy Summary
    PayerConnectiCare
    PolicyViltepso (viltolarsen) Coverage Criteria
    Policy CodePolicy C20585-A
    Change TypeNo material clinical or coverage changes
    Effective DateJun 6, 2026
    Next Review DateApr 1, 2027
    Key ActionSubmit patient records, test results, and provider credentials when requested for coverage determination.
    SourceLink
    On This Page
    Coverage DeterminationCoding InformationProvider and Billing GuidanceDrug and Disease BackgroundKey Definitions
    Denial Risk

    Insufficient evidence or unsupported medical necessity

    Coverage may be denied because Viltepso is considered not medically necessary for all indications, including Duchenne muscular dystrophy, due to insufficient evidence of therapeutic value and the lack of an established clinical benefit. Reimbursement may also be denied if submitted documentation does not support medical necessity, non-investigational status, benefit eligibility, or appropriate billing and utilization.

    Denial Risk

    Non-labeled use

    Use of Viltepso (viltolarsen) for indications other than the applicable labeled use is considered experimental or investigational and follows the payer’s Off-Label policy.

    Denial Risk

    Other uses are experimental or investigational

    Uses of Viltepso other than the policy-supported uses are considered experimental or investigational and follow the Molina Off-Label policy.

    Billing Rule

    Improper billing or noncovered benefit

    Submit claims accurately and only for covered benefits under the applicable benefit document. The claim may be denied or payment may be recovered if the service is billed incorrectly or is not a covered benefit.

    • Listing a code in the policy does not guarantee coverage.
    • HCPCS J1427 is listed for injection, viltolarsen, 10 mg.
    Amenable to exon 53 skipping
    DefinitionA genetic DMD variant for which viltolarsen is intended to promote exon skipping and dystrophin production; the study described participants with DMD amenable to exon 53 skipping.